December 3-5, 2019 | Boston, MA, USA
www.oncolyticvirotherapies.com

ONCOLYTIC VIROThERAPY Summit

Optimize the Immune Response to Cancer with Viral Vehicles
The roadmap to oncolytic virotherapy success

Expert Speakers Include:

Maritza McIntyre
Former Chief Gene Therapy Branch
FDA

Lance Weed
Vice President Operations
UniQure

Shara DellaTore
Principal Scientist and Group Leader
Merck

Angelica Loksog
Chief Executive Officer
Lokon Pharma

Sridhar Pennathur
Senior Director and Fellow
Biopharmaceutical Development
AstraZeneca

Lorena Lerner
Vice President Molecular Biology and Virology
Oncorus

Event Partner:
O.D.260 Inc.
ADENOVIRUS EXPERT

Tel: +1 617 455 4188  Mail: info@hansonwade.com
Welcome to the 5th Oncolytic Virotherapy Summit (OV) 2019

The industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications.

Hear from pharma and biotech companies of all sizes, as well as clinicians and leading academics to harness the unique activity of OVs warming up tumors and advance these therapies through the clinic.

Discover the development of oncolytic viruses that engage the immune system for long-term treatment and management of cancers.

Join the leading minds in Oncolytic Virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies.

100+ Attendees
8+ Hours of Networking

Five Unmissable Highlights

Compelling Case Studies
Hear 8 indepth case studies from the likes of Astrazeneca, Oncorus and Merck to name a few as they share the latest advances in oncolytic virus development

Diverse Discussions
Our panels bring together multi-specialty, cross background professionals to discuss the biggest challenges such as Intra-tumoral vs. intra-venous administration with Oncolytics and K9 biotech

The Big Picture
From case studies on novel genes with Unleash to the blueprint for an internal manufacturing system with Western Oncolytics - the OV Summit covers the full development process from inception to commercialization

Productive Networking
Have constructive conversations with all the stakeholders in this industry from the FDA on the complex regulatory landscape to Merck on viral vehicle comparison

Hands-on Workshops
We believe in practical learning and nothing champions this better than dedicated in depth workshops on designing and developing manufacturing capabilities with uniQure and Harnessing the immune system in pediatric oncology with Oncorus

Hear what previous attendees have to say

"Great opportunity to mingle with the key players in the field of Oncolytic Virotherapy and learn from the experts"
Tooba Cheema, Director Translational Medicine & Biomarkers, Oncorus

"The Oncolytic Virotherapy Summit is an awesome opportunity to network, to learn what has been happening in the OV field and also what to expect in the future"
Past Attendee from Boehringer Ingelheim

"Excellent meeting with substantive content"
Past Attendee from Tocagen Inc.
AN UNRIVALED SPEAKER LINE-UP

Louis Cantolupo  
Chief Operating Officer  
Unleash Immuno Oncolytics

Rob Coffin  
Chief Executive Officer  
Replimune

Shara Dellatore  
Principal Scientist and Group Leader  
Merck

Dr Erik Digman Wiklund  
Chief Business Officer  
Targovax ASA

Dr John Goldberg  
Senior Vice President Clinical Development and Practicing Paediatric Oncologist  
Oncorus

Dr Brian Haines  
Senior Director Pharmacology  
Oncorus

Daniel Katzman  
Chief Executive Officer  
Unleash Immuno-Oncolytics

Lorena Lerner  
Vice President Molecular Biology and Virology  
Oncorus

Angelica Loksog  
Chief Executive Officer  
Lokon Pharma

Maritza McIntyre  
President, Advanced Therapies Partners and Former Chief of Gene Therapy  
FDA

Beatriz Mesa  
Senior Director Oncolytic Virus Manufacturing  
Sorrento Therapeutics

Michael Moore  
Vice President Investor Relations and Corporate Communications  
Oncolytics Biotech

Sridhar Pennathur  
Senior Director and Fellow Biopharmaceutical Development  
AstraZeneca

Christophe Queva  
Chief Scientific Officer  
Oncorus

David Sherris  
Ph.D., President and Chief Executive Officer  
GenAdam Therapeutics

Steve Thorne  
Chief Scientific Officer  
Western Oncolytics

Lance Weed  
Vice President Operations  
UniQure

Mr. Michael Wood  
MBA, Founder and Chief Operating Officer  
OncoMyx Therapeutics

Anton Xavier  
Founder  
K9 Biotech

The oncolytic virotherapy summit is a great mixture of researchers and early to late companies. To visit the meeting gives a good overview of leading as well as upcoming oncolytic viruses, and a view on the current advantages and hurdles within many complex questions within the filed.

Angelica Loksog, CEO, Lokon Pharma
## Keynote Panels

### 8.40 Panel: One Vision for the Future of Oncolytic Virotherapies
- The next generation of OV therapies – combination therapy or modified mono-therapy?
- Consider the role of transgenes and checkpoint inhibitors
- Look to possible indications beyond cancer – are virotherapy drugs translatable to other gene therapies?

**Moderator:** Rob Coffin  
Chief Executive Officer  
Replimune

**Panellists:**
- Dr Erik Digman Wiklund  
Chief Business Officer  
Targovax ASA
- Shara Deliatore  
Principal Scientist and Group Leader  
Merck
- Lorena Lerner  
Vice President  
Molecular Biology and Virology  
Oncorus

### 9.20 Panel: To IT or to IV? Intra-Tumoural vs Intra-Venous Administration
- Decide whether OV treatments are most effective when injected directly into the tumour or systemically
- Weigh the risks of IT administration with the benefits of a more targeted approach
- Consider the views of physician

**Moderator:** Christophe Queva  
Chief Scientific Officer  
Oncorus

**Panellists:**
- Daniel Katzman  
Chief Executive Officer  
Unleash Immuno-Oncolytics
- Michael Moore  
Vice President  
Investor Relations and Corporate Communications  
Oncolytics Biotech
- Anton Xavier  
Founder  
K9 Biotech

## The Latest Advances in Research

### 11.30 Case Study: Comparative Oncology in Domesticated Canines and Humans
- Translate efficacious canine read-outs to human patients
- Systemic infiltration to target cancer regardless of tumour micro-environment through IV administration and up-regulation of receptors in the tumour
- Creation of an effective mono-therapy through the use of transgenes making the requirement of combination therapies with checkpoint inhibitors obsolete

**Moderator:**
Anton Xavier  
Founder  
K9 Biotech

**Panellists:**
- Sridhar Pennathur  
Senior Director and Fellow  
Biopharmaceutical Development  
AstraZeneca

### 11.50 Case Study: Considerations When Using Vaccinia Virus as a Vector for Oncolytic Vaccines
- Harnessing the potent immune response of the Pox Virus
- Inserting genes into complex viruses
- Purification and safety testing on a commercial scale

**Moderator:**
Dr Brian Haines  
Senior Director Pharmacology  
Oncorus

### 12.10 Case Study: The Benefits of Monotherapies and Combination Based on Disease Indication
- Creation of an effective monotherapy through the use of transgenes
- ONCR-177 express PD-1 and CTLA4 antagonists data supporting monotherapy benefits and combination with ICI in varying indications
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30</td>
<td><strong>Q&amp;A Panel</strong></td>
</tr>
<tr>
<td></td>
<td>• The audience take the mic (and control) with questions for our speakers</td>
</tr>
<tr>
<td>13.00</td>
<td><strong>Lunch Seminar</strong></td>
</tr>
<tr>
<td></td>
<td>Maximise productivity by pairing food with food-for-thought at the optional lunchtime seminar.</td>
</tr>
<tr>
<td>13.00</td>
<td><strong>Lunch Networking Break</strong></td>
</tr>
<tr>
<td>14.00</td>
<td><strong>Case Study: Proprietary I23 armed oncolytic</strong></td>
</tr>
<tr>
<td></td>
<td>• Target stromal based cancers, including ovarian and lung, via systemic administration by including genetically engineered antibodies in the OV</td>
</tr>
<tr>
<td></td>
<td>• Modify the viral vector to tailor to specific disease indications</td>
</tr>
<tr>
<td></td>
<td>• Amend the virus to use as a monotherapy in cancers which cannot tolerate checkpoint inhibitors such as ovarian cancer</td>
</tr>
<tr>
<td>14.20</td>
<td><strong>Targovax’s ONCOS-102 in the Treatment of PD-1 Refractory Melanoma</strong></td>
</tr>
<tr>
<td></td>
<td>• Phase I ORR and immune data</td>
</tr>
<tr>
<td></td>
<td>• Combination with KEYTRUDA checkpoint inhibitor</td>
</tr>
<tr>
<td>14.40</td>
<td><strong>OncoMyx’s Systemic Administration of EV2</strong></td>
</tr>
<tr>
<td></td>
<td>• Pox virus platform with large Genome for easy transgene modification</td>
</tr>
<tr>
<td></td>
<td>• Solid tumour focus across indications</td>
</tr>
<tr>
<td>15.00</td>
<td><strong>Q&amp;A Panel</strong></td>
</tr>
<tr>
<td></td>
<td>• The audience take the mic (and control) with questions for our speakers</td>
</tr>
<tr>
<td>15.20</td>
<td><strong>Afternoon Networking Break</strong></td>
</tr>
<tr>
<td>15.50</td>
<td><strong>Panel: Viral Vehicle Comparison</strong></td>
</tr>
<tr>
<td></td>
<td>• Target specific tumour microenvironments by identifying the most effective virus</td>
</tr>
<tr>
<td></td>
<td>• Consider the packaging capacity of the virus and the limitations on the size of DNA that can be cloned into it</td>
</tr>
<tr>
<td></td>
<td>• Decide whether viruses are the best vector for the novel genes needed to create an effective immuno-oncology therapy</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>Speed Learning</strong></td>
</tr>
<tr>
<td></td>
<td>Take this opportunity to leverage expertise from the audience as well as the expert speaker faculty in short burst roundtable sessions</td>
</tr>
<tr>
<td>15.00</td>
<td><strong>Poster Session and Drinks Reception</strong></td>
</tr>
<tr>
<td></td>
<td>Constructive conversations over cocktails and canapés to the backdrop of posters.</td>
</tr>
</tbody>
</table>

“This kind of conference will be more desirable than academic conference for actual development in the market. very valuable encounter will be the key benefit derived from the conference!”

Past Attendee from Kyushu University Hospital
# DAY TWO
**THURSDAY 5 DECEMBER 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Welcome Coffee</td>
</tr>
<tr>
<td>9.30</td>
<td>Chair’s Opening Remarks</td>
</tr>
</tbody>
</table>
| 9.40    | **Case Study: Encourage Patient Participation and Retention**  
Tocagen  
Angelica Loksog  
Chief Executive Officer  
Lokon Pharma  
- Increase awareness of your trial by tailoring your message directly to patients and their carers  
- Utilizing AI and innovation for earlier identification of relevant patients and online targeting  
- Ensure patient retention by designing the trial with the patient in mind – embrace technological advances for smoother patient services and check-ins |
| 10.10   | **Case Study: LOAd703 Virus in Pancreatic Cancer Clinical Trial**  
Tocagen  
Angelica Loksog  
Chief Executive Officer  
Lokon Pharma  
- Presentation of efficacy and immunology data and clinical trial design  
- Increased anti-tumour reactive T-cells in patient blood during treatment |
| 10.40   | Morning Networking Break          |
| 11.10   | **Non-Clinical Safety Studies**   
Maritza McIntyre  
Former Chief Gene Therapy Branch  
FDA  
- Preclinical evaluation of complex products including cell and gene therapy examples  
- Assessing safety for OV therapies that will not replicate in species used in toxicology studies and expressed transgenes that will not function outside of human biology |
| 11.40   | **Case Study: Navigating the Complex Regulatory Landscape**  
Shara Dellatore  
Principal Scientist and Group Leader  
Merck  
- Monitor virus shedding and bio distribution in animal models and consider regulatory guidance around these issues  
- Understand the safety implications of OV therapies from an early stage to ensure regulatory compliance |
| 12.10   | **Case Study: Manufacturing Vaccinia Virus on a Commercial Scale**  
Steve Thorne  
Chief Scientific Officer  
Western Oncolytics  
- Development of a novel back-bone vector  
- Manufacturing of an OV that is administered systemically and contains a transgene |
| 12.40   | **Panel: The Case For and Against Internalizing the Manufacturing Process**  
Beatriz Mesa  
Senior Director  
Oncolytic Virus Manufacturing  
Sorrento Therapeutics  
Lance Weed  
Vice President Operations  
UniQure  
Steve Thorne  
Chief Scientific Officer  
Western Oncolytics  
Louis Cantolupo  
Chief Operating Officer  
Unleash Immuno-Oncolytics  
- The draw-backs of working with a contract manufacturing organization  
- Obstacles faced when developing an internal manufacturing process  
- The processes that can prove difficult during the development of the process – purification, quality control and storage |
| 13.20   | Chair’s Closing Remarks           |
| 13.30   | Lunch Break                       |
| 14.30   | **Wrap Up Roundtables**           
- 10 tables, 10 problems, 10 solutions. Ready, set, resolve! |
| 16.00   | Networking Coffee to Stay or Go   |
How to Design and Develop an Internal Manufacturing Capability

- Develop process with plan to transition to large-scale commercial production to meet regulatory requirements
- Structure all manufacturing operations to reduce potential failure points and ensure reproducibility
- Design facility with flexibility for process change or future business requirements
- Ensure facility design controls for viral containment, material flow, people flow, product flow, sample flow and waste flow

Workshop Leader

Lance Weed
Vice President Operations
uniQure

Lance Weed has more than 30 years of extensive experience in the design, construction, process development, manufacturing and establishment of operations for biopharmaceutical facilities including drug substance and drug product lines where no prior manufacturing capability was established. This includes uniQure’s multiproduct gene therapy facility utilizing 100% disposable process systems for drug substance and drug product. Lance also built BioVex’s oncolytic virus production facility which is currently the commercial production facility for Imlygic under Amgen’s ownership. Lance has a degree in Chemical Engineering from University of New Hampshire.

Harness the Natural Ability of the Immune System in Paediatric Oncology

- Biology of childhood tumours and how this differentiates from adult cancers
- Learnings from paediatric immunotherapy that can be applied to adult indications
- Understanding the tumour response to virus injection and modulating this response by altering the tumour micro-environment

Workshop Leader

John Goldberg
Senior Vice President Clinical Development and Practicing Paediatric Oncologist
Oncorus

John Goldberg is the Senior Vice President of Clinical Development at Oncorus, Inc. a Cambridge, MA based oncolytic virus therapy company advancing both intratumoral and systemic approaches. A practicing pediatric oncologist, Dr. Goldberg previously led the pediatric oncology phase 1 clinical trials program at the University of Miami prior to joining industry. In Miami, he led studies in children and adults using a variety of modalities including cellular and targeted therapy, and treated patients with leukemia, brain tumors and sarcoma. He made the leap to biotech to help bring a seasoned clinical perspective to drug development, and has developed immunotherapy and RNA targeted treatments subsequently. Responsible for all of clinical development at Oncorus, Dr. Goldberg is passionate about bringing new therapies to patients with unmet medical needs, including children with difficult to treat cancers.
Why the Oncolytic Virotherapy Summit?
The 5th Oncolytic Virotherapy Summit is the fastest route to in-depth discussions with organizations prioritizing oncolytic virus drug development. The OV Summit provides an unrivalled opportunity for your brand, your message and your reputation to be showcased in front of the leading minds of the growing ‘Oncology Virus Industry’.

Who do I get to meet?
Gathering stakeholders and key opinion leaders, this is the ultimate opportunity to position yourself as an expert in front of 100+ drug developers. Elevate your company’s standing and influence the future of oncolytic virus drug development.

What can OV do for you?
Elevate your brand; Engage industry decision makers; Demonstrate thought leadership
We understand each business is different so we’ll work with you to build a bespoke partnership opportunity to fulfil your commercial objectives.

Event Partner
OD260 Inc is your ideal partner for the pre-clinical development of oncolytic adenovirus vectors. With more than 20 years’ experience in the field, we will help you with the design and construction of your vector and the generation of validated virus stocks for in vitro and animal studies (up to $10^{15}$ VP). QC tests include confirmation of virus identity (genome sequencing), physical and infectious titer (VP/IU), genetic and thermal stability, and verification of transgene expression

www.od260.com

TYPICAL ATTENDANCE BY SECTOR

<table>
<thead>
<tr>
<th>Sector</th>
<th>Attendance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Developers</td>
<td>65%</td>
</tr>
<tr>
<td>Academic Institute</td>
<td>10%</td>
</tr>
<tr>
<td>Service Provider</td>
<td>10%</td>
</tr>
<tr>
<td>Investors</td>
<td>5%</td>
</tr>
</tbody>
</table>

TYPICAL ATTENDANCE SENIORITY

- C-level: 19%
- President/VP: 26%
- Head/Director: 32%
- Scientist/Professor: 23%

*Based on market research and previous events’ statistics

How is OV different?
At this year’s Oncolytic Virotherapy Summit, you can expect:

- **A HIGHER CALIBRE OF CONVERSATIONS:** with over 8 hours of networking you’ll have more opportunities than ever for significant discussions with your key prospects
- **DEDICATED ICEBREAKER SESSIONS FROM THE START:** starting a conversation is never easy, so let us start them for you
- **INTERACTIVE SESSIONS AS STANDARD:** engage your audience in solution focused exchanges at this year’s panel discussions, speed learning roundtables and poster session

Luke O’Neill
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

GET INVOLVED

Tel: +1 617 455 4188   Mail: info@hansonwade.com
www.oncolyticvirotherapies.com
READY TO REGISTER?

3 EASY WAYS TO BOOK

www.oncolyticvirotherapies.com
Tel: +1 617 455 4188
Email: register@hansonwade.com

SECURE YOUR PLACE

Package Details  | Register & Pay before September 6 | Save up to $300  | Standard Prices
---|---|---|---
**GOLD**  
Conference + 2 Workshops | $3399  | $3699
**SILVER**  
Conference + 1 Workshop | $2999  | $3299
**BRONZE**  
Conference Only | $2399  | $2699

Workshops (Each)  | Price upon request

Make OV 2019 a team trip:

- 10% discount – 2 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial dispute, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH.

Academics and Small Biotechs are entitled to a 40% discount off industry pricing. Eligibility criteria for Small Biotechs states that the company needs to be less than 5 years old AND fewer than 10 full time employees. Software and service providers are excluded. Email info@hansonwade.com to enquire about the rate or apply. All bookings at this rate are subject to organizer approval. T&Cs apply.

VENUE

The Westin Boston Waterfront  
425 Summer Street, Boston, Massachusetts 02210
For further information or assistance, please visit www.marriott.com

www.oncolyticvirotherapies.com